Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- A diagnosis of leukemia throws a family into turmoilon November 26, 2021 at 11:32 am
Without assistance, tens of thousands of children like this brave brother and sister may have to chalk up Christmas to just another disappointing day. But Globe Santa will step in.
- Study uncovers important genetic predispositions for acute myeloid leukemiaon November 24, 2021 at 5:05 pm
The National Center for Tumor Diseases Dresden is a joint institution of the German Cancer Research Center, the University Hospital Carl Gustav Carus Dresden, Carl Gustav Carus Faculty of Medicine at ...
- Patient death prompts clinical trial pause for Kura Oncology leukemia drugon November 24, 2021 at 11:50 am
The FDA placed a partial clinical hold on a Kura Oncology leukemia drug following the death of one patient in the early-stage study. Kura executives said the death may be related to differentiation ...
- AML Study Placed Under Partial Hold Following Patient Deathon November 24, 2021 at 9:01 am
Shares of Kura Oncology have plunged nearly 30% in premarket trading after the San Diego-based company announced the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on the ...
- FDA Halts KOMET-001 Study for Acute Myeloid Leukemia Due to Safetyon November 24, 2021 at 6:11 am
The phase 1b KOMET-001 has been suspended while the developer of KO-539 and FDA investigate a serious safety event.
- FDA halts phase 1b Kura Oncology trial in acute myeloid leukemia following patient deathon November 24, 2021 at 5:55 am
A patient has died in a Kura Oncology phase 1b trial in people with acute myeloid leukemia leading the FDA to place a clinical hold on the study. The investigational oral treatment was potentially ...
- Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemiaon November 24, 2021 at 3:47 am
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food ...
- Porter County police fundraise for officer diagnosed with acute myeloid leukemiaon November 23, 2021 at 7:00 am
After an officer was suddenly diagnosed with acute myelogenous leukemia, the Porter County Sheriff's staff have rallied together to gather support. Porter County Sheriff's Office has launched a ...
- AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemiaon November 22, 2021 at 9:23 am
AUTHORIZATION TO INITIATE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) AB8939 IS A NEW GENERATION SYNTHETIC MICROTUBULE DESTABILIZER WITH THE ABILITY TO OVERCOME ...
- Quizartinib regimen extends OS for certain patients with acute myeloid leukemiaon November 22, 2021 at 8:07 am
The addition of quizartinib to chemotherapy extended OS for certain adults with newly diagnosed acute myeloid leukemia, according to topline data released by the agent’s manufacturer.AML accounts for ...
via Bing News